10 Stocks Insiders Sold in April After Trump’s Tariff Rollout

3. Zai Lab Limited (NASDAQ:ZLAB)

Zai Lab Limited is a biopharmaceutical company focused on developing and commercializing treatments for oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula for ovarian cancer, VYVGART for myasthenia gravis, and NUZYRA for bacterial infections, among others. Headquartered in Shanghai, China, Zai Lab collaborates with various pharmaceutical companies to advance its pipeline of innovative therapies. It is also considered one of the 10 best performing growth stocks in 2025.

Recently, Zai Lab announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) to treat recurrent or metastatic cervical cancer. Dr. Rafael Amado, President of Global Research and Development, highlighted that TIVDAK could provide significant benefits for patients with limited treatment options. The results from the global clinical trial demonstrated a 45% reduction in the risk of death compared to chemotherapy in clinical trials.

This month, seven insiders, including the company’s CEO, and CFO, sold around $1.65 million worth of Zai Lab shares at an average price of $34.50 per share. Following these sales the stock price dropped to $25.13, losing 4.05% year-to-date. However, over the past 12 months, Zai Lab gained 56.87%.

According to TipRanks, five Wall Street analysts rate Zai Lab stock as a “Strong Buy” with a price target of $54.03 per share. This suggests a potential upside of 113.64% from the latest price.